VICC toll-free number
1-877-936-8422

The VICC.ORG Directory of Cancers: Treatments, Services & Resources

Gynecologic Cancers

Vanderbilt Ingram Cancer Center's Division of Gynecologic Oncology specializes in the prevention, diagnosis and treatment of gynecologic malignancy, including ovarian cancer, cervical cancer, and endometrial cancer.

Types of Gynecologic Cancer

Treatment at Vanderbilt

Gynecologic Cancer News


Clinical Trials for Gynecologic Cancers

4 Open Trials

Trial Type &
Disease		Protocol No. &
Open Date		Summary
Therapeutic
Uterine
VICCGYN1174
09/26/2012
A Phase II, Open-Label, Single-Arm, Non-Randomized, Multi-Center Study to Evaluate the Efficacy of Oral TKI258 as Second-Line Therapy in Patients with Either FGFR2 Mutated or Wild-Type Advanced and/or Metastatic Endometrial Cancer
Therapeutic
Gynecologic;
Ovarian
VICCGYN1206
09/25/2012
A phase II randomized open label study of MM-121 in combination with paclitaxel versus paclitaxel alone in patients with platinum resistant/refractory advanced ovarian cancers
Therapeutic
Adrenocortical;
Bladder;
Breast;
Cervical;
Colon;
Dermatologic;
Esophageal;
GIST;
Gastric/Gastroesophageal;
Gynecologic;
Head/Neck;
Kidney (Renal Cell);
Liver;
Lung;
Multiple Myeloma;
Neuroendocrine;
Ovarian;
Pancreatic;
Prostate;
Rectal;
Sarcoma;
Small Cell;
Uterine
VICCMD1188
06/08/2012
An Open-Label, Phase II Study of Vemurafenib in Patients with BRAF V600 Mutation-Positive Cancers
Screen, Detect, Diagnose
Adrenocortical;
Bladder;
Breast;
Cervical;
Colon;
Dermatologic;
Esophageal;
GIST;
Gastric/Gastroesophageal;
Gynecologic;
Head/Neck;
Kidney (Renal Cell);
Liver;
Lung;
Multiple Myeloma;
Neuroendocrine;
Ovarian;
Pancreatic;
Prostate;
Rectal;
Sarcoma;
Small Cell;
Uterine
VICCMD1286
12/17/2012
Screening Protocol to Detect BRAF V600 Mutation Positive Patients for Enrollment into Clinical Research Studies of Vemurafenib

You do not have JavaScript enabled. This site works better with JavaScript turned on.